WE BELIEVE

the upper nasal space to be a gateway for improved absorption and hence, the potential for enhanced clinical outcomes.

 

The POD devices are designed to deliver a range of therapeutic molecules and formulations deep into the vascular-rich upper nasal space. This unique combination has the potential to deliver consistent and predictable doses of drug, potentially enabling on-demand access for molecules previously limited to injection and hospital-based use.

Indication
Preclinical
Phase 1
Phase 2
Phase 3
FDA Approved
Next anticipated milestone

Migraine

Acute Agitation and Aggression associated with ASD

Morning OFF Episodes in Parkinson’s

TRUDHESATM (dihydroergotamine mesylate) — nasal spray (0.725 mg per spray)

INP105 (Olanzapine) — Phase 1 completed

INP107 (Levodopa/Carbidopa) — Phase 2a


By YE:2021
Initiate Phase 2 proof-of-concept clinical trial
2H:2022
Announce Phase 2 topline results

2022
Initiate INP107 PK study for pivotal dose selection

Acute Migraine
Acute Agitation and Aggression associated with ASD
Morning OFF Episodes in Parkinson’s
FDA Approved
Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray)

Phase 3
Phase 2
INP105 (Olanzapine) — Phase 1 completed
By YE:2021

Initiate Phase 2 proof-of-concept clinical trial

2H:2022

Announce Phase 2 topline results

INP107 (Levodopa/Carbidopa) — Phase 2a
2022

Initiate INP107 PK study for pivotal dose selection

Phase 1

With this proprietary platform, Impel is aiming to improve the consistency and predictability of the delivery of many proven therapeutics that target CNS disorders.